Victoria Corvest, Perrine Marec-Bérard, Cyril Lervat, Hélène Pacquement, Maud Toulmonde, Jean-Claude Gentet, Valérie Laurence, Morgane Cleirec, Ludovic Mansuy, Emmanuelle Bompas, Marie-Pierre Castex, Sophie Taque, Bruno Filhon, Marie-Dominique Tabone, Cécile Verité, Natacha Entz-Werle, Laure Saumet, Gregory Guimard, Morgane Pondrom, Christine Chevreau, Jennifer Flandrin, Lise Duranteau, Christine Rousset-Jablonski, Laurence Brugières, Marta Jimenez, Marie-Cécile Le Deley, Nathalie Gaspar, Brice Fresneau
In Euro-EWING99-R1 randomized trial, cyclophosphamide was shown to be noninferior to ifosfamide in the consolidation of standard-risk Ewing sarcoma (SR-EWS) after a common induction with VIDE (vincristine-ifosfamide-doxorubicin-etoposide). We present the results of the late effects analysis of VAC (vincristine-dactinomycin-cyclophoshamide) vs VAI (vincristine-dactinomycin-ifosfamide) conducted in Euro-EWING99-R1 French cohort. Of 267 French randomized patients, 204 were alive and free-of-relapse at 5-years including 172 with available long-term follow-up data concerning cardiac, renal and/or gonadal functions (sex-ratio M/F = 1...
April 15, 2023: International Journal of Cancer. Journal International du Cancer